abs293.txt	background		cancer	causes	significant	morbidity	and	mortality	among	hiv	patientsin	the	us	due	to	extended	life	expectancy	with	access	to	effective	antiretroviraltherapy		low		detectable	hiv	rna	has	been	studied	as	a	risk	factor	for	adversehealth	outcomes		but	its	clinical	impact	on	cancer	risk	remains	unclear		theobjective	of	this	study	was	to	determine	whether	hiv	rna	<1	000	copies/ml	sixmonths	after	starting	therapy	was	associated	with	10-year	first	cancer	risk	methods		we	followed	7	515	hiv	therapy	initiators	from	a	us-based	multicenterclinical	cohort	from	1998	to	2014		we	used	nonparametric	multiple	imputation	toaccount	for	viral	loads	that	fell	below	assay	detection	limits		and	categorizedviral	loads	six	months	after	therapy	initiation	into	four	groups		<20		20-199	200-999		and	>999	copies/ml		we	calculated	estimates	of	the	cumulative	incidenceof	cancer	diagnosis		accounting	for	death	as	a	competing	event		inverseprobability	of	exposure	and	censoring	weights	were	used	to	control	forconfounding	and	differential	loss	to	follow	up		respectively	results		crude	10-year	first	cancer	risk	in	the	study	sample	was	7	03%	(95%	ci	6	08%		7	98%)		with	the	highest	risk	observed	among	patients	with	viral	loadsbetween	200	and	999	copies/ml	six	months	after	art	initiation	(10	7%)		aftercontrolling	for	baseline	confounders		10-year	first	cancer	risk	was	6	90%	(95%ci		5	69%		8	12%)		and	was	similar	across	viral	load	categories	conclusion		overall	risk	of	first	cancer	was	not	associated	with	incomplete	viralsuppression		however		cancer	remains	a	significant	threat	to	hiv	patients	aftertreatment	initiation		as	more	hiv	patients	gain	access	to	treatment	in	thecurrent		treat	all		era		occurrences	of	incomplete	viral	suppression	will	beobserved	more	frequently	in	clinical	practice		which	supports	continued	study	ofthe	role	of	low-level	hiv	rna	on	cancer	development	
